Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 165.11 Billion KRW | 126.6% |
| 2022 | 151.07 Billion KRW | 19.1% |
| 2021 | 126.84 Billion KRW | 9.82% |
| 2020 | 115.5 Billion KRW | 3.3% |
| 2019 | 111.81 Billion KRW | 6.82% |
| 2018 | 104.67 Billion KRW | 7.8% |
| 2017 | 97.09 Billion KRW | 5.63% |
| 2016 | 91.91 Billion KRW | 0.17% |
| 2015 | 91.76 Billion KRW | 4.98% |
| 2014 | 87.4 Billion KRW | -6.63% |
| 2013 | 93.61 Billion KRW | 5.45% |
| 2012 | 88.76 Billion KRW | 7.85% |
| 2011 | 82.3 Billion KRW | -1.4% |
| 2010 | 83.47 Billion KRW | 57.13% |
| 2009 | 53.12 Billion KRW | -18.54% |
| 2008 | 65.21 Billion KRW | 2.03% |
| 2007 | 63.92 Billion KRW | 9.22% |
| 2006 | 58.52 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 47.13 Billion KRW | 1.72% |
| 2024 Q1 | 46.34 Billion KRW | -45.99% |
| 2023 Q2 | -40.71 Billion KRW | -200.68% |
| 2023 Q1 | 40.44 Billion KRW | -4.96% |
| 2023 Q4 | 85.8 Billion KRW | 302.71% |
| 2023 Q3 | -42.33 Billion KRW | -3.97% |
| 2023 FY | 342.33 Billion KRW | 126.6% |
| 2022 Q1 | 35.6 Billion KRW | 3.73% |
| 2022 Q3 | 36.2 Billion KRW | -1.37% |
| 2022 Q4 | 42.55 Billion KRW | 17.53% |
| 2022 FY | 151.07 Billion KRW | 19.1% |
| 2022 Q2 | 36.7 Billion KRW | 3.09% |
| 2021 Q1 | 30.72 Billion KRW | 0.47% |
| 2021 FY | 126.84 Billion KRW | 9.82% |
| 2021 Q2 | 31.21 Billion KRW | 1.6% |
| 2021 Q3 | 30.58 Billion KRW | -2.0% |
| 2021 Q4 | 34.32 Billion KRW | 12.23% |
| 2020 Q4 | 30.57 Billion KRW | 12.45% |
| 2020 Q3 | 27.19 Billion KRW | -4.77% |
| 2020 Q2 | 28.55 Billion KRW | -2.16% |
| 2020 FY | 115.5 Billion KRW | 3.3% |
| 2020 Q1 | 29.18 Billion KRW | 4.17% |
| 2019 Q4 | 28.01 Billion KRW | 1.66% |
| 2019 Q2 | 28.48 Billion KRW | 2.6% |
| 2019 Q1 | 27.76 Billion KRW | 0.0% |
| 2019 FY | 111.81 Billion KRW | 6.82% |
| 2019 Q3 | 27.55 Billion KRW | -3.24% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 FY | 104.67 Billion KRW | 7.8% |
| 2018 Q2 | 26.37 Billion KRW | 11.06% |
| 2018 Q1 | 23.74 Billion KRW | -10.46% |
| 2018 Q3 | 26.08 Billion KRW | -1.11% |
| 2017 Q3 | 25 Billion KRW | 9.81% |
| 2017 FY | 97.09 Billion KRW | 5.63% |
| 2017 Q4 | 26.52 Billion KRW | 6.09% |
| 2017 Q1 | 22.8 Billion KRW | -9.56% |
| 2017 Q2 | 22.76 Billion KRW | -0.15% |
| 2016 FY | 91.91 Billion KRW | 0.17% |
| 2016 Q1 | 20.43 Billion KRW | -16.82% |
| 2016 Q2 | 23.61 Billion KRW | 15.59% |
| 2016 Q3 | 22.65 Billion KRW | -4.07% |
| 2016 Q4 | 25.21 Billion KRW | 11.29% |
| 2015 Q1 | 21.36 Billion KRW | -22.62% |
| 2015 Q4 | 24.56 Billion KRW | 0.13% |
| 2015 Q3 | 24.53 Billion KRW | 15.17% |
| 2015 Q2 | 21.3 Billion KRW | -0.3% |
| 2015 FY | 91.76 Billion KRW | 4.98% |
| 2014 Q2 | 21.04 Billion KRW | 13.72% |
| 2014 Q1 | 18.5 Billion KRW | -24.22% |
| 2014 FY | 87.4 Billion KRW | -6.63% |
| 2014 Q4 | 27.61 Billion KRW | 36.3% |
| 2014 Q3 | 20.25 Billion KRW | -3.72% |
| 2013 Q3 | 24.04 Billion KRW | 4.01% |
| 2013 FY | 93.61 Billion KRW | 5.45% |
| 2013 Q1 | 22.02 Billion KRW | -3.89% |
| 2013 Q2 | 23.12 Billion KRW | 4.95% |
| 2013 Q4 | 24.41 Billion KRW | 1.52% |
| 2012 Q4 | 22.92 Billion KRW | 7.11% |
| 2012 Q1 | 21.73 Billion KRW | -7.8% |
| 2012 Q2 | 22.71 Billion KRW | 4.52% |
| 2012 FY | 88.76 Billion KRW | 7.85% |
| 2012 Q3 | 21.39 Billion KRW | -5.8% |
| 2011 FY | 82.3 Billion KRW | -1.4% |
| 2011 Q2 | 18.4 Billion KRW | 2.27% |
| 2011 Q4 | 23.57 Billion KRW | 5.57% |
| 2011 Q1 | 17.99 Billion KRW | -5.2% |
| 2011 Q3 | 22.32 Billion KRW | 21.3% |
| 2010 Q3 | 21.6 Billion KRW | -7.91% |
| 2010 Q4 | 18.98 Billion KRW | -12.11% |
| 2010 Q1 | 19.51 Billion KRW | 0.0% |
| 2010 FY | 83.47 Billion KRW | 57.13% |
| 2010 Q2 | 23.45 Billion KRW | 20.22% |
| 2009 Q2 | 18.25 Billion KRW | 13.54% |
| 2009 Q1 | 16.07 Billion KRW | 3.8% |
| 2009 FY | 53.12 Billion KRW | -18.54% |
| 2009 Q3 | 15.94 Billion KRW | -12.65% |
| 2008 FY | 65.21 Billion KRW | 2.03% |
| 2008 Q3 | 15.99 Billion KRW | -9.46% |
| 2008 Q4 | 15.48 Billion KRW | -3.18% |
| 2008 Q2 | 17.66 Billion KRW | 13.5% |
| 2008 Q1 | 15.56 Billion KRW | -0.68% |
| 2007 Q4 | 15.67 Billion KRW | -9.65% |
| 2007 FY | 63.92 Billion KRW | 9.22% |
| 2007 Q2 | 15.34 Billion KRW | 0.0% |
| 2007 Q3 | 17.34 Billion KRW | 13.04% |
| 2006 FY | 58.52 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -249.417% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 44.591% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 40.7% |
| HANDOK Inc. | 153.76 Billion KRW | -7.378% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -138.556% |
| Yuhan Corporation | 489.94 Billion KRW | 66.3% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 46.21% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -295.107% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 72.975% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -129.377% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 5.188% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -312.236% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -76.494% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -43.921% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -249.417% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -288.76% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -120.007% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -181.551% |
| JW Holdings Corporation | 301.25 Billion KRW | 45.192% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 36.728% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 59.596% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 30.889% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -29.329% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -141.708% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -151.117% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 5.61% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -249.417% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 33.722% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 70.538% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 30.889% |
| Yuhan Corporation | 489.94 Billion KRW | 66.3% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 14.742% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -137.681% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -194.676% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 30.889% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -30.635% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -39.673% |
| CKD Bio Corp. | 25.19 Billion KRW | -555.322% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 25.624% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -148.6% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -29.329% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 52.921% |
| Boryung Corporation | 285.16 Billion KRW | 42.098% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -88.61% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 5.188% |
| JW Lifescience Corporation | 20.26 Billion KRW | -714.909% |